PHARMOCANN GLOBAL LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 112.9 ILa | +5.12% |
|
+5.12% | -19.41% |
| Mar. 31 | Pharmocann Global Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Pharmocann Global Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 173.8 | 132.8 | 40.73 | 9.927 | 3.121 |
| Enterprise Value (EV) 1 | 159.3 | 121.8 | 34.47 | 9.002 | 2.353 |
| P/E ratio | -3.21 x | 36.7 x | -2.08 x | -0.26 x | -0.28 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 8.33 x | 4.75 x | 1.41 x | 0.44 x | 0.22 x |
| EV / Revenue | 7.63 x | 4.36 x | 1.19 x | 0.4 x | 0.16 x |
| EV / EBITDA | 20.8 x | 18.2 x | -2.38 x | -0.47 x | -0.25 x |
| EV / FCF | -318 x | -33.1 x | 4.43 x | -2.71 x | -2.35 x |
| FCF Yield | -0.31% | -3.02% | 22.6% | -37% | -42.5% |
| Price to Book | 5.5 x | 3.23 x | 1.6 x | 1.28 x | 4.1 x |
| Nbr of stocks (in thousands) | 661 | 661 | 679 | 1,334 | 2,228 |
| Reference price 2 | 263.2 | 201.0 | 60.00 | 7.440 | 1.401 |
| Announcement Date | 4/23/20 | 3/29/21 | 3/31/22 | 3/31/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 14.77 | 20.88 | 27.93 | 28.96 | 22.66 | 14.41 |
| EBITDA 1 | 9.128 | 7.658 | 6.708 | -14.47 | -18.98 | -9.319 |
| EBIT 1 | 8.454 | 6.935 | 6.101 | -15.89 | -20.29 | -9.491 |
| Operating Margin | 57.22% | 33.21% | 21.84% | -54.87% | -89.54% | -65.85% |
| Earnings before Tax (EBT) 1 | 8.376 | -44.49 | 6.056 | -22.37 | -24.48 | -9.734 |
| Net income 1 | 6.396 | -46.46 | 3.619 | -19.35 | -25.26 | -9.734 |
| Net margin | 43.29% | -222.5% | 12.96% | -66.8% | -111.47% | -67.54% |
| EPS | - | -82.00 | 5.479 | -28.80 | -28.92 | -4.947 |
| Free Cash Flow 1 | -1.246 | -0.5006 | -3.676 | 7.779 | -3.327 | -1 |
| FCF margin | -8.43% | -2.4% | -13.16% | 26.86% | -14.68% | -6.94% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 4/8/19 | 4/23/20 | 3/29/21 | 3/31/22 | 3/31/23 | 3/31/24 |
1ILS in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2.81 | 14.5 | 11 | 6.26 | 0.93 | 0.77 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.25 | -0.5 | -3.68 | 7.78 | -3.33 | -1 |
| ROE (net income / shareholders' equity) | 79.6% | -217% | 9.95% | -58.2% | -152% | -228% |
| ROA (Net income/ Total Assets) | 41.3% | 15.4% | 8.05% | -22% | -47.3% | -47.1% |
| Assets 1 | 15.48 | -301.7 | 44.93 | 87.87 | 53.44 | 20.66 |
| Book Value Per Share 2 | 23.90 | 47.90 | 62.20 | 37.40 | 5.820 | 0.3400 |
| Cash Flow per Share 2 | 3.280 | 21.70 | 17.00 | 9.470 | 1.820 | 0.4100 |
| Capex 1 | 1.23 | 0.59 | 1.28 | 1.46 | 1.3 | 0.03 |
| Capex / Sales | 8.32% | 2.83% | 4.59% | 5.06% | 5.73% | 0.23% |
| Announcement Date | 4/8/19 | 4/23/20 | 3/29/21 | 3/31/22 | 3/31/23 | 3/31/24 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -19.41% | 742K | |
| -.--% | 339M | |
| +33.33% | 261M | |
| +39.53% | 182M | |
| +164.52% | 150M | |
| -33.33% | 137M | |
| +50.41% | 136M | |
| -28.57% | 121M | |
| -7.69% | 80.3M | |
| +100.00% | 60.26M |
- Stock Market
- Equities
- PMCN-M Stock
- Financials Pharmocann Global Ltd
